Uncategorized
AI Uses MRIs to Generate Brain Aging Maps for Neurodegenerative Disease Research
Researchers at the University of Southern California have developed an approach that uses artificial intelligence to generate detailed maps that highlight differences in how distinct parts of the brain age. The researchers, led by associate professor Andrei Irimia, PhD, at the USC Leonard Davis School of Gerontology, used magnetic resonance imaging (MRI) from nearly 15,000 cognitively healthy individuals to train a deep learning AI model. The data provided a baseline against which the model could measure local brain age (LBA), or how old specific regions of the brain appear.
While most studies of brain age measure this phenomenon using a single number, the new model provides a much richer picture of typical aging and neurodegeneration. Rather than assigning a single “brain age” (BA) to an individual, the approach generates a detailed map showing how old different parts of the brain appear relative to what is typical for someone of the same chronological age.
When the AI model was then used to analyze MRI images from people with mild cognitive impairment and Alzheimer’s disease (AD), it revealed distinct patterns of accelerated aging in brain regions known to be affected early in neurodegeneration.
“Not all brain regions age at the same rate,” Irimia said. “Some areas appear to be more resilient, while others are more vulnerable to aging and disease. By measuring local brain aging, we can identify where the brain is aging faster than expected and how those changes relate to cognitive function.”
In their in paper in PNAS, titled “Deep learning maps local brain aging in relation to cognition across human adulthood,” senior author Irimia and colleagues stated, “By providing spatially resolved measures of brain aging, this work enables more precise investigation of how neuroanatomic alterations and cognitive impairment affect brain anatomy, above and beyond global brain age measures.”
Aging is a prominent risk factor for the onset of brain diseases, including Alzheimer’s disease and related dementias, the authors wrote. “One of the most prominent biological features of brain aging is atrophy, i.e., brain volume decrease that often involves loss of brain cells and neural connectivity.”
The newly reported research builds on previous efforts to estimate BA, an emerging neuroimaging biomarker that compares a person’s brain structure to patterns seen in healthy people across the lifespan. But while human brain aging is not uniform across cortical regions, traditional methods typically reduce the brain to a single age estimate, which can obscure important regional differences. The new approach instead measures local brain age at the voxel level—the three-dimensional units that make up an MRI scan—producing a much more detailed picture of structural aging throughout the brain.
“This more nuanced understanding of how the brain ages could pave the way for earlier identification of dementia, a better understanding of what factors affect risk and new ideas for treatment approaches,” Irimia said.
To develop the model, the researchers trained a deep-learning neural network using MRI scans from 14,748 cognitively normal adults ages 19 years to 100 years, drawn from six large public datasets, including the UK Biobank, the Human Connectome Project and the Alzheimer’s Disease Neuroimaging Initiative. The team then tested the model using MRI scans from more than 1,900 additional participants in the Alzheimer’s Disease Neuroimaging Initiative, including cognitively normal adults, people with mild cognitive impairment and people with Alzheimer’s disease.
Across healthy adults, the model consistently found that the frontal and temporal lobes—regions involved in decision-making, memory and other higher cognitive functions—appeared biologically older than the parietal and occipital regions, which are involved in spatial awareness and sensory processing functions. “Our approach consistently reveals spatial patterns of aging, including relatively advanced aging in frontal and temporal regions, across both typical aging and Alzheimer’s disease,” the investigators noted. The researchers also found that the brain’s right hemisphere tended to show slightly more advanced aging than the left, a pattern that persisted regardless of whether participants were right- or left-handed.
As cognitive impairment progressed, the differences became even more pronounced. Compared with cognitively normal adults, participants with mild cognitive impairment (MCI) or Alzheimer’s disease showed significantly older local brain ages in structures that are among the first affected by Alzheimer’s pathology, including the hippocampus, amygdala and several deep brain regions involved in memory and cognitive processing.
The researchers also found that older local brain age was associated with poorer performance on cognitive assessments, strengthening the link between structural brain changes and real-world function. “Deviations from normative regional aging are significantly associated with cognitive performance supported by neural processes linked to those regions … thereby relating anatomic aging to functional outcomes,” they stated. The strongest relationships appeared in people with Alzheimer’s disease, suggesting that regional brain aging may become increasingly informative as neurodegeneration advances.
Because the model produces anatomically detailed maps, it could eventually help scientists better understand why some people experience faster decline in specific cognitive abilities than others. The approach may also prove useful for tracking disease progression or evaluating whether experimental therapies are slowing degeneration in targeted brain regions. “By providing spatially resolved measures of brain aging, this work enables more precise investigation of how neuroanatomic alterations and cognitive impairment affect brain anatomy, above and beyond global brain age measures,” they commented.
Although the findings are promising, Irimia emphasized that the method remains a research tool. The model was trained primarily on research-quality MRI data and will require additional validation using more diverse clinical datasets before it can be adopted in routine patient care. The study also relied largely on cross-sectional data, meaning that future longitudinal studies will be needed to determine whether local brain aging can reliably predict who will progress from healthy aging to mild cognitive impairment or Alzheimer’s disease.
Still, the researchers believe that moving beyond a single measure of brain age represents an important advance for neuroscience. “By quantifying the anatomy of brain aging and aligning it with cognition and disease stage, this work establishes a foundation for mechanistic inquiry and personalized intervention in neurodegeneration,” the authors stated. “This scalable framework paves the way for monitoring a broad spectrum of neurodegenerative and aging related disorders,” Irimia added, “Brain aging isn’t uniform. “By understanding how individual regions age, as well as how those patterns differ from person to person, we’re moving toward a much more precise understanding of healthy aging and neurodegenerative disease. Ultimately, that could help us identify people at risk earlier and develop more personalized approaches to preserving brain health.”
The post AI Uses MRIs to Generate Brain Aging Maps for Neurodegenerative Disease Research appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read